CER Daily Newsfeed

Video: Trump Administration Should Focus on Fixing IRA, 340B: John M. O'Brien, PharmD, MPH

(4/30, Julia Bonavitacola, Christina Mattina, John Michael O'Brien, PharmD, MPH, The American Journal of Managed Care) “...[John M. O'Brien, PharmD, MPH:] Now, our research and the work of others has identified that the Inflation Reduction Act will delay launches, reduce the number of subsequent indications, and have a chilling effect on postapproval outcomes research...On the 340B side, our research has identified that 340B is not a victimless crime that only takes money from pharmaceutical manufacturers. It's costing employers, it's costing states, and that's ultimately costing patients.” View Video

Medicare Administrator Explores Cutting Red Tape for Health Insurance Approvals

(4/29, Rachel Cohrs Zhang, Bloomberg) reports “...The aim of the proposals would be to cut the number of medical procedures subject to ‘prior authorization,’ meaning ones in which doctors have to fill out additional paperwork for ultimate approval. CMS is exploring making policies more uniform across different health insurance plans. Another goal is automating coverage determinations so patients can get decisions faster, said the people, who weren’t authorized to speak publicly on the matter.” Subscription Required

NIH Launches Real-World Data Platform to Advance Autism Research and Broader Health Goals

(4/30, Katie McCool, The Evidence Base) reports “The National Institutes of Health (NIH) is launching a real-world data (RWD) platform to support research into autism spectrum disorder (ASD) and chronic diseases, NIH Director Dr Jay Bhattacharya announced during the April 21, 2025 Council of Councils meeting. The platform will integrate disparate datasets across federal agencies and the private sector to support research aimed at understanding the causes, treatments, and progression of ASD and other complex conditions.” Full

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

(4/30, Neena Brizmohun, Pink Sheet) reports “...Drug companies that are considering using artificial intelligence (AI)-informed evidence in the health technology assessment dossiers they submit in Canada should engage early with the country’s HTA agency, the CDA-AMC, possibly by seeking scientific advice.” Subscription Required